BIAL appoints Max Bricchi as Chief Commercial Officer

BIAL appoints Max Bricchi as Chief Commercial Officer


BIAL has announced the appointment of Max Bricchi as Chief Commercial Officer (CCO) and Executive Board member. With responsibility for the entire global commercial operations, Max Bricchi’s focus will be to consolidate the company's internationalization strategy, based on the growth of BIAL's current and future portfolio, namely its innovative medicines, bringing BIAL solutions to people living with severe diseases across the world.

Max Bricchi has over twenty-five years of experience and leadership across Regional and Global Strategy, Marketing, Commercial, and end-to-end Portfolio Management. He brings broad experience in the pharmaceutical industry from several roles, having a strong track record in pre-launch and launch of products across several therapeutical areas, including neurology, rheumatology, gastroenterology, dermatology, and rare diseases.

António Portela, BIAL’s Chief Executive Officer, stated that “it is an enormous satisfaction to be able to have Max on board. With his extensive leadership experience, he will certainly help leverage the company's growth in our main markets, providing it with a structure that is increasingly prepared for the challenges we have set ourselves, based on a truly international dimension and anchored in innovative launches”.

“Being part of the Board of Directors and Chief Commercial Officer at BIAL is an exciting challenge”, says Max Bricchi. “I have been following BIAL's remarkable path, centred on innovation for patients, and I’m excited to work with teams across the world to keep providing our medicines to all people living with severe diseases, strengthening the company's current and future portfolio”.

Max Bricchi joins BIAL from Novartis (HQ, Basel, Switzerland) where, since 2020, he served as the Global Head Neuroscience Franchise.

For 15 years, from 2005 to 2020, Max Bricchi served at UCB Pharma, where he undertook different positions in various locations of the company: Global Head Epilepsy Franchise; Japan, China and International Markets Head Neurology - both positions in Belgium -; Latin America Region Managing Director in Mexico; US Group Director Immunology and Global and US Brand Director Biologics in the United States.

Max Bricchi’s also worked at Schering-Plough as Global Product Manager Immunology, in the US, and then in Germany as Immunology Division Manager.

Max Bricchi holds an MBA from IMD Lausanne, a Master’s in Quality Management from Buenos Aires Technologic Institute and a degree as Industrial Engineer from the University of Buenos Aires, Argentina.

BIAL appoints Max Bricchi as Chief Commercial Officer

No results found according to criteria